These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 35220871)

  • 21. Osilodrostat: First Approval.
    Duggan S
    Drugs; 2020 Apr; 80(5):495-500. PubMed ID: 32141023
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Selectivity of osilodrostat as an inhibitor of human steroidogenic cytochromes P450.
    Valentín-Goyco J; Liu J; Peng HM; Oommen J; Auchus RJ
    J Steroid Biochem Mol Biol; 2023 Jul; 231():106316. PubMed ID: 37098354
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Osilodrostat (Isturisa) for Cushing's disease.
    Med Lett Drugs Ther; 2021 Feb; 63(1617):21-23. PubMed ID: 33647005
    [No Abstract]   [Full Text] [Related]  

  • 24. Medical Treatment of Cushing's Disease: An Overview of the Current and Recent Clinical Trials.
    Pivonello R; Ferrigno R; De Martino MC; Simeoli C; Di Paola N; Pivonello C; Barba L; Negri M; De Angelis C; Colao A
    Front Endocrinol (Lausanne); 2020; 11():648. PubMed ID: 33363514
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Long-term efficacy and safety of osilodrostat in Cushing's disease: final results from a Phase II study with an optional extension phase (LINC 2).
    Fleseriu M; Biller BMK; Bertherat J; Young J; Hatipoglu B; Arnaldi G; O'Connell P; Izquierdo M; Pedroncelli AM; Pivonello R
    Pituitary; 2022 Dec; 25(6):959-970. PubMed ID: 36219274
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Updates on the role of adrenal steroidogenesis inhibitors in Cushing's syndrome: a focus on novel therapies.
    Fleseriu M; Castinetti F
    Pituitary; 2016 Dec; 19(6):643-653. PubMed ID: 27600150
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Osilodrostat in Cushing's disease: the management of its efficacy and the pitfalls of post-surgical results.
    Antonini S; Brunetti A; Zampetti B; Boeris D; Saladino A; Cesare Cozzi R
    Endocrinol Diabetes Metab Case Rep; 2022 Nov; 2022():. PubMed ID: 36515363
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Long-term efficacy and safety of osilodrostat in patients with Cushing's disease: results from the LINC 4 study extension.
    Gadelha M; Snyder PJ; Witek P; Bex M; Belaya Z; Turcu AF; Feelders RA; Heaney AP; Paul M; Pedroncelli AM; Auchus RJ
    Front Endocrinol (Lausanne); 2023; 14():1236465. PubMed ID: 37680892
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Osilodrostat: A Novel Potent Inhibitor of 11-Beta-Hydroxylase for the Treatment of Cushing's Syndrome.
    Pivonello R; Simeoli C; Di Paola N; Larocca A; Crescenzo EM; Colao A
    touchREV Endocrinol; 2024 Apr; 20(1):43-51. PubMed ID: 38812665
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cushing's disease: role of preoperative and primary medical therapy.
    Castinetti F
    Pituitary; 2022 Oct; 25(5):737-739. PubMed ID: 35780261
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Advances in the medical treatment of Cushing's syndrome.
    Feelders RA; Newell-Price J; Pivonello R; Nieman LK; Hofland LJ; Lacroix A
    Lancet Diabetes Endocrinol; 2019 Apr; 7(4):300-312. PubMed ID: 30033041
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cushing's syndrome: a combined treatment with etomidate and osilodrostat in severe life-threatening hypercortisolemia.
    Dzialach L; Sobolewska J; Respondek W; Wojciechowska-Luzniak A; Witek P
    Hormones (Athens); 2022 Dec; 21(4):735-742. PubMed ID: 36129663
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Medical therapy for Cushing's disease: adrenal steroidogenesis inhibitors and glucocorticoid receptor blockers.
    Fleseriu M; Petersenn S
    Pituitary; 2015 Apr; 18(2):245-52. PubMed ID: 25560275
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Differences in the spectrum of steroidogenic enzyme inhibition between Osilodrostat and Metyrapone in ACTH-dependent Cushing syndrome patients.
    Bonnet-Serrano F; Poirier J; Vaczlavik A; Laguillier-Morizot C; Blanchet B; Baron S; Guignat L; Bessiene L; Bricaire L; Groussin L; Assié G; Guibourdenche J; Bertherat J
    Eur J Endocrinol; 2022 Aug; 187(2):315-322. PubMed ID: 35699971
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy and Safety of Osilodrostat in Managing Cushing's Syndrome: A Systematic Review and Meta-Analysis.
    Nagendra L; Dutta D; Raizada N; Surana V; Selvan C; Bhattacharya S
    Indian J Endocrinol Metab; 2024; 28(3):232-238. PubMed ID: 39086571
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Drug Interaction Potential of Osilodrostat (LCI699) Based on Its Effect on the Pharmacokinetics of Probe Drugs of Cytochrome P450 Enzymes in Healthy Adults.
    Armani S; Ting L; Sauter N; Darstein C; Tripathi AP; Wang L; Zhu B; Gu H; Chun DY; Einolf HJ; Kulkarni S
    Clin Drug Investig; 2017 May; 37(5):465-472. PubMed ID: 28155129
    [TBL] [Abstract][Full Text] [Related]  

  • 37. LCI699, a potent 11β-hydroxylase inhibitor, normalizes urinary cortisol in patients with Cushing's disease: results from a multicenter, proof-of-concept study.
    Bertagna X; Pivonello R; Fleseriu M; Zhang Y; Robinson P; Taylor A; Watson CE; Maldonado M; Hamrahian AH; Boscaro M; Biller BM
    J Clin Endocrinol Metab; 2014 Apr; 99(4):1375-83. PubMed ID: 24423285
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Randomized Trial of Osilodrostat for the Treatment of Cushing Disease.
    Gadelha M; Bex M; Feelders RA; Heaney AP; Auchus RJ; Gilis-Januszewska A; Witek P; Belaya Z; Yu Y; Liao Z; Ku CHC; Carvalho D; Roughton M; Wojna J; Pedroncelli AM; Snyder PJ
    J Clin Endocrinol Metab; 2022 Jun; 107(7):e2882-e2895. PubMed ID: 35325149
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Osilodrostat treatment in patients with Cushing's disease of Asian or non-Asian origin: a pooled analysis of two Phase III randomized trials (LINC 3 and LINC 4).
    Shimatsu A; Biller BM; Fleseriu M; Pivonello R; Lee EJ; Leelawattana R; Kim JH; Walia R; Yu Y; Liao Z; Piacentini A; Pedroncelli AM; Snyder PJ
    Endocr J; 2024 Dec; 71(12):1103-1123. PubMed ID: 39183039
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Case Report: Consecutive Adrenal Cushing's Syndrome and Cushing's Disease in a Patient With Somatic
    Detomas M; Altieri B; Schlötelburg W; Appenzeller S; Schlaffer S; Coras R; Schirbel A; Wild V; Kroiss M; Sbiera S; Fassnacht M; Deutschbein T
    Front Endocrinol (Lausanne); 2021; 12():731579. PubMed ID: 34489873
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.